[144] Incyte Genomics Inc SEC Filing
Incyte Genomics' Form 144 records a proposed sale of 75,963 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,267,540.00. The shares were acquired via a stock option exercise on 08/13/2025 and payment was made in cash.
The filing also lists insider sales by Barry Flannelly totaling 27,472 shares in the past three months for gross proceeds of $2,040,893.53. The issuer reports 195,276,145 shares outstanding, so the proposed sale equals approximately 0.039% of outstanding shares. The document contains no earnings, guidance, or other operational details.
Il modulo 144 di Incyte Genomics registra una proposta di vendita di 75.963 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $6.267.540,00. Le azioni sono state ottenute con l'esercizio di un'opzione su azioni il 13/08/2025 e il pagamento 猫 stato effettuato in contanti.
La comunicazione indica inoltre vendite interne da parte di Barry Flannelly per un totale di 27.472 azioni negli ultimi tre mesi, per proventi lordi di $2.040.893,53. L'emittente dichiara 195.276.145 azioni in circolazione, quindi la vendita proposta corrisponde a circa 0,039% del totale. Il documento non contiene informazioni sugli utili, guidance o altri dettagli operativi.
El Formulario 144 de Incyte Genomics registra una propuesta de venta de 75.963 acciones comunes a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $6.267.540,00. Las acciones se adquirieron mediante el ejercicio de una opci贸n sobre acciones el 13/08/2025 y el pago se realiz贸 en efectivo.
La presentaci贸n tambi茅n detalla ventas por parte del insider Barry Flannelly por un total de 27.472 acciones en los 煤ltimos tres meses, por ingresos brutos de $2.040.893,53. El emisor informa 195.276.145 acciones en circulaci贸n, por lo que la venta propuesta equivale aproximadamente al 0,039% de las acciones en circulaci贸n. El documento no contiene beneficios, previsiones ni otros detalles operativos.
Incyte Genomics鞚� Form 144電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 75,963 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 旮半頄堨溂氅�, 齑� 鞁滉皜齑濎暋鞚� $6,267,540.00鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 欤检嫕鞓奠厴 頄夓偓搿� 2025雲� 8鞗� 13鞚�鞐� 旆摑霅橃棃瓿�, 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟.
氤搓碃靹滌棎電� 霕愴暅 雮措秬鞛� Barry Flannelly臧� 歆�雮� 3臧滌洈臧� 齑� 27,472欤茧ゼ 毵る弰頃橃棳 齑濍Г於滌澊 $2,040,893.53鞛勳澊 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆靷姅 195,276,145欤缄皜 氚滍枆霅橃柎 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 霐半澕靹� 鞝滌晥霅� 毵り皝鞚� 氚滍枆欤检嫕鞚� 鞎� 0.039%鞐� 頃措嫻頃╇媹雼�. 氍胳劀鞐愲姅 靾橃澋, 臧�鞚措崢鞀� 霕愲姅 旮绊儉 鞖挫榿 甏�霠� 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le formulaire 144 d'Incyte Genomics enregistre une proposition de vente de 75 963 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande totale de $6 267 540,00. Les actions ont 茅t茅 acquises par exercice d'option sur actions le 13/08/2025 et le paiement a 茅t茅 effectu茅 en 别蝉辫猫肠别蝉.
Le d茅p么t mentionne 茅galement des cessions par l'initi茅 Barry Flannelly totalisant 27 472 actions au cours des trois derniers mois, pour des produits bruts de $2 040 893,53. L'茅metteur d茅clare 195 276 145 actions en circulation, de sorte que la vente propos茅e repr茅sente environ 0,039 % des actions en circulation. Le document ne contient ni informations sur les b茅n茅fices, ni pr茅visions, ni autres d茅tails op茅rationnels.
Das Formular 144 von Incyte Genomics verzeichnet einen geplanten Verkauf von 75.963 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $6.267.540,00. Die Aktien wurden durch die Aus眉bung einer Aktienoption am 13.08.2025 erworben und bar bezahlt.
Die Einreichung nennt au脽erdem Insider-Verk盲ufe von Barry Flannelly in H枚he von insgesamt 27.472 Aktien innerhalb der letzten drei Monate mit Bruttoerl枚sen von $2.040.893,53. Der Emittent meldet 195.276.145 ausstehende Aktien, sodass der vorgeschlagene Verkauf etwa 0,039 % der ausstehenden Aktien entspricht. Das Dokument enth盲lt keine Angaben zu Gewinnen, Prognosen oder anderen operativen Details.
- None.
- None.
Insights
TL;DR Routine insider liquidity: planned sale is modest relative to outstanding shares and follows recent smaller disposals.
The proposed disposition of 75,963 shares for $6.27M appears to be an execution of compensation-related liquidity after a stock option exercise. Compared with the issuer's 195.28M shares outstanding, the planned sale represents about 0.039%, a negligible dilution or market-pressure signal on its own. Recent insider activity shows 27,472 shares sold for $2.04M over the past three months, indicating ongoing personal liquidity rather than a one-off large exit. No financial results or new material company information are included in the filing.
TL;DR Disclosure is standard and complies with Rule 144 mechanics; no governance red flags in form content.
The filing documents a sale routed through an institutional broker and includes required acquisition details (stock option exercise) and payment method (cash), which supports procedural transparency. The identity shown in past sales, Barry Flannelly, and the broker (Morgan Stanley Smith Barney LLC) are explicitly listed. Because the amounts are small relative to total outstanding shares and the form contains no undisclosed operational issues, this notice is a routine insider reporting event rather than a governance concern.
Il modulo 144 di Incyte Genomics registra una proposta di vendita di 75.963 azioni ordinarie tramite Morgan Stanley Smith Barney LLC sul NASDAQ, per un valore di mercato complessivo di $6.267.540,00. Le azioni sono state ottenute con l'esercizio di un'opzione su azioni il 13/08/2025 e il pagamento 猫 stato effettuato in contanti.
La comunicazione indica inoltre vendite interne da parte di Barry Flannelly per un totale di 27.472 azioni negli ultimi tre mesi, per proventi lordi di $2.040.893,53. L'emittente dichiara 195.276.145 azioni in circolazione, quindi la vendita proposta corrisponde a circa 0,039% del totale. Il documento non contiene informazioni sugli utili, guidance o altri dettagli operativi.
El Formulario 144 de Incyte Genomics registra una propuesta de venta de 75.963 acciones comunes a trav茅s de Morgan Stanley Smith Barney LLC en el NASDAQ, con un valor de mercado agregado de $6.267.540,00. Las acciones se adquirieron mediante el ejercicio de una opci贸n sobre acciones el 13/08/2025 y el pago se realiz贸 en efectivo.
La presentaci贸n tambi茅n detalla ventas por parte del insider Barry Flannelly por un total de 27.472 acciones en los 煤ltimos tres meses, por ingresos brutos de $2.040.893,53. El emisor informa 195.276.145 acciones en circulaci贸n, por lo que la venta propuesta equivale aproximadamente al 0,039% de las acciones en circulaci贸n. El documento no contiene beneficios, previsiones ni otros detalles operativos.
Incyte Genomics鞚� Form 144電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 75,963 氤错喌欤茧ゼ 毵る弰頃� 鞓堨爼鞛勳潉 旮半頄堨溂氅�, 齑� 鞁滉皜齑濎暋鞚� $6,267,540.00鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 欤检嫕鞓奠厴 頄夓偓搿� 2025雲� 8鞗� 13鞚�鞐� 旆摑霅橃棃瓿�, 雽�旮堨潃 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟.
氤搓碃靹滌棎電� 霕愴暅 雮措秬鞛� Barry Flannelly臧� 歆�雮� 3臧滌洈臧� 齑� 27,472欤茧ゼ 毵る弰頃橃棳 齑濍Г於滌澊 $2,040,893.53鞛勳澊 旮办灛霅橃柎 鞛堨姷雼堧嫟. 氚滍枆靷姅 195,276,145欤缄皜 氚滍枆霅橃柎 鞛堧嫟瓿� 氤搓碃頄堨溂氅�, 霐半澕靹� 鞝滌晥霅� 毵り皝鞚� 氚滍枆欤检嫕鞚� 鞎� 0.039%鞐� 頃措嫻頃╇媹雼�. 氍胳劀鞐愲姅 靾橃澋, 臧�鞚措崢鞀� 霕愲姅 旮绊儉 鞖挫榿 甏�霠� 靹鸽秬靷暛鞚� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
Le formulaire 144 d'Incyte Genomics enregistre une proposition de vente de 75 963 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande totale de $6 267 540,00. Les actions ont 茅t茅 acquises par exercice d'option sur actions le 13/08/2025 et le paiement a 茅t茅 effectu茅 en 别蝉辫猫肠别蝉.
Le d茅p么t mentionne 茅galement des cessions par l'initi茅 Barry Flannelly totalisant 27 472 actions au cours des trois derniers mois, pour des produits bruts de $2 040 893,53. L'茅metteur d茅clare 195 276 145 actions en circulation, de sorte que la vente propos茅e repr茅sente environ 0,039 % des actions en circulation. Le document ne contient ni informations sur les b茅n茅fices, ni pr茅visions, ni autres d茅tails op茅rationnels.
Das Formular 144 von Incyte Genomics verzeichnet einen geplanten Verkauf von 75.963 Stammaktien 眉ber Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $6.267.540,00. Die Aktien wurden durch die Aus眉bung einer Aktienoption am 13.08.2025 erworben und bar bezahlt.
Die Einreichung nennt au脽erdem Insider-Verk盲ufe von Barry Flannelly in H枚he von insgesamt 27.472 Aktien innerhalb der letzten drei Monate mit Bruttoerl枚sen von $2.040.893,53. Der Emittent meldet 195.276.145 ausstehende Aktien, sodass der vorgeschlagene Verkauf etwa 0,039 % der ausstehenden Aktien entspricht. Das Dokument enth盲lt keine Angaben zu Gewinnen, Prognosen oder anderen operativen Details.
